Examkin

Soru

Zorluk: Çok zorGynecologic Oncology

A 68-year-old woman presents to the clinic reporting recurrent, light vaginal bleeding for the past 4 months. Three months ago, she was evaluated at an outside facility for the initial onset of this symptom. At that time, a transvaginal ultrasound was performed, demonstrating a homogeneous endometrial stripe of 2.6 mm and normal-appearing ovaries. A Pap test was negative for intraepithelial lesion or malignancy. She was diagnosed with genitourinary syndrome of menopause and prescribed vaginal estrogen therapy. The patient has been using the estrogen cream twice weekly as directed, but reports that the intermittent spotting has persisted. She takes no other medications and has no history of abnormal Pap smears. Vital signs are within normal limits. Pelvic examination reveals a well-rugated, moist vaginal mucosa. The cervix appears nulliparous and grossly normal, with a small amount of dark blood noted at the external os. The uterus is small, mobile, and non-tender, with no palpable adnexal masses. Which of the following is the most appropriate next step in management?

  1. Endometrial biopsyCevap
  2. B
    Repeat transvaginal ultrasonography
  3. C
    Discontinuation of vaginal estrogen and clinical observation
  4. D
    Saline infusion sonohysterography
  5. E
    Endometrial ablation

Cevap

Endometrial biopsy
In a postmenopausal woman, any vaginal bleeding is considered abnormal and warrants investigation for endometrial cancer. The initial evaluation can involve either a transvaginal ultrasound or an endometrial biopsy. If an ultrasound is chosen and demonstrates an endometrial stripe of 4 mm or less, the risk of malignancy is exceedingly low (< 1%), and observation is reasonable if the bleeding resolves. However, if the bleeding is persistent or recurrent, tissue sampling is strictly required. This is because Type II endometrial cancers (such as serous or clear cell carcinomas) are estrogen-independent, arise in atrophic endometrium, and frequently present with an endometrial thickness of less than 4 mm. Therefore, despite the previously reassuring ultrasound and the concurrent use of vaginal estrogen, this patient's persistent bleeding mandates an endometrial biopsy.

Adım Adım Çözüm

1
Analyze the patient's clinical presentation and timeline of symptoms.
The patient is a postmenopausal woman with persistent vaginal bleeding despite a prior reassuring ultrasound (endometrial stripe < 4 mm) and appropriate treatment for vaginal atrophy.
Establishing the sequence of evaluations determines if the standard initial algorithm has already been exhausted.
2
Evaluate the reliability of the prior transvaginal ultrasound.
While an endometrial stripe of 4 mm or less generally confers a < 1% risk of malignancy, it is not an absolute guarantee of benignity.
Standard guidelines state that observation is only appropriate if the bleeding stops after a reassuring ultrasound.
3
Identify the underlying pathological risk factor for this specific presentation.
Type II endometrial carcinomas (e.g., papillary serous, clear cell) are estrogen-independent, can arise from an atrophic endometrium, and frequently present with an endometrial thickness of less than 4 mm.
Understanding the pathogenesis of Type II cancers explains why the 'thin stripe' rule has exceptions.
4
Determine the definitive next step in management.
Tissue sampling is mandatory to rule out malignancy.
Persistent postmenopausal bleeding overrides previous reassuring imaging, making an endometrial biopsy the required next step.

Anahtar Kavram

In postmenopausal bleeding, persistent symptoms despite an initial transvaginal ultrasound showing an endometrial stripe <= 4 mm mandate an endometrial biopsy to rule out Type II endometrial carcinoma.
Bu soruyu puanla

Konular

Gynecologic Oncology

Bu konudan daha fazla soru